Diagonal Bio AB: Stall Goop conducts pilot test of LAMPlify®
Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") has signed an agreement with Stall Goop regarding a pilot test of LAMPlify®. The three-month pilot test, starting in February 2025, aims to enhance equine health and performance by enabling early detection of potential virus infections in horses.
Stall Goop is located in Kil, Värmland, and is run by Björn Goop. As a world-leading trotting trainer, Björn Goop has more than 8,000 victories and is thus Sweden's most victorious trotting trainer of all time. Stall Goop currently carries 150 horses.
Diagonal Bio has since 2024 focused its efforts on introducing LAMPlify® to the equine diagnostics sector. The pilot test at Stall Goop will further support the Company's efforts to enhance equine health in high-performance environments.
"If LAMPlify® can provide a fast diagnostic solution for horses it will be a game-changer and I am excited to test and evaluate the platform together with Diagonal Bio" - Björn Goop, owner of Stall Goop
"We are happy to share the news that Stall Goop has decided to conduct a pilot test of LAMPlify®, and we are very much looking forward to showing what we have to offer with regards to equine and overall animal health" - Karin Wehlin, CEO of Diagonal Bio AB (publ)
This press release contains inside information that Diagonal Bio AB (publ) is required to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on 5 February, 2025, at 19:45 CET.
For additional information about Diagonal Bio, please contact:
Karin Wehlin, CEO
Phone: +46 703 052488
E-mail: kw@diagonalbio.com
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
E-mail: ca@skmg.se
About Diagonal Bio
Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.